Max Robotics — Global Service Robot Directory + US Certification

About

Chris Neff is a translational researcher whose work sits at the intersection of ovarian cancer genomics and precision oncology. His most impactful contributions center on the clinical validation of homologous recombination deficiency (HRD) as a predictive biomarker for targeted therapy. In his landmark 2022 study, cited over 40 times, Neff led the diagnostic evaluation of HRD in a real-world cohort of 514 ovarian carcinoma samples. By employing next-generation sequencing of DNA libraries—including comprehensive analysis of BRCA1/BRCA2 alongside 26,523 single-nucleotide variants—he demonstrated how genomic profiling can be systematically integrated into routine clinical practice to identify patients most likely to benefit from PARP inhibitors. This work has directly shaped how oncologists stratify treatment strategies for advanced ovarian cancer. Neff’s research is notable for bridging the gap between high-throughput sequencing technology and actionable clinical decision-making, providing a reproducible framework for HRD testing that has been adopted in multiple cancer centers. His findings underscore the importance of real-world evidence in validating biomarkers that were initially discovered in controlled trial settings, making him a key figure in the movement toward genomically guided cancer care.